Clinical characteristics of patients with MA-ILD who failed conventional treatment and received adjunctive tacrolimus (n = 18). Values are n unless otherwise specified.
| Clinical Characteristics | Responders, n = 13 | No Response, n = 5 | p |
|---|---|---|---|
| Age at onset of myositis, yrs | 41.8 | 43.0 | 1.00 |
| Sex | |||
| Male | 6 | 2 | 0.62 |
| Female | 7 | 3 | |
| Race | |||
| Black | 5 | 4 | 0.49 |
| White | 7 | 1 | |
| Asian | 0 | 0 | |
| Hispanic | 1 | 0 | |
| Smoking history | |||
| Never | 10 | 4 | 1.00 |
| Former | 2 | 0 | |
| Active | 1 | 1 | |
| Myositis | |||
| Polymyositis | 6 | 3 | 0.50 |
| Dermatomyositis | 7 | 2 | |
| CADM | 0 | 0 | |
| Baseline CK, U/l | 4353.5 | 1975.7 | 0.60 |
| Baseline aldolase | 31.0 | 43.8 | 0.64 |
| Serologic data | |||
| ANA | 10 | 2 | 0.18 |
| Anti-Jo1 | 6 | 0 | 0.09 |
| SSA | 5 | 2 | 0.68 |
| Mi-2 | 2 | 0 | 0.51 |
| PL-7 | 0 | 1 | 0.28 |
| SRP | 1 | 0 | 0.72 |
| Ku | 1 | 0 | 0.72 |
| PFT, % | |||
| FVC | 63.7 | 42.4 | 0.010 |
| TLC | 65.9 | 45.0 | 0.042 |
| DLCO | 52.2 | 56.4 | 0.49 |
| CT chest | |||
| Honeycombing absent | 9 | 5 | 0.23 |
| Honeycombing present | 4 | 0 | |
| Lung histopathology | |||
| COP | 2 | 0 | N/A |
| UIP | 2 | 0 | |
| NSIP | 2 | 0 | |
| Others* | 1 | 0 | |
| Conventional DMARD | |||
| AZA | 8 | 5 | 0.15 |
| MTX | 4 | 4 | 0.088 |
| MMF | 3 | 1 | 0.70 |
↵* COP with NSIP, COP with hypersensitivity pneumonitis, and COP with diffuse alveolar damage. MA-ILD: myositis-associated interstitial lung disease; CADM: clinically amyopathic dermatomyositis; CK: creatine kinase; ANA: antinuclear antibody; SRP: signal recognition particle; PFT: pulmonary function test; FVC: forced vital capacity; TLC: total lung capacity; CT: computed tomography; COP: cryptogenic organizing pneumonia; UIP: usual interstitial pneumonia; NSIP: nonspecific interstitial pneumonia; DMARD: disease-modifying antirheumatic drugs; AZA: azathioprine; MTX: methotrexate; MMF: mycophenolate mofetil; N/A: not applicable.